Pulmonology & Thoracic Medicine

Severe Asthma

Biologic therapy (omalizumab, mepolizumab, dupilumab) and bronchial thermoplasty for severe asthma.

Treatment Options

Recommended Centers

$6,000

Starting From

7-21 days

Typical Wait

Treatment Plans for Severe Asthma

Compare evidence-based options at top Chinese hospitals — transparent pricing, typical wait, and recovery time.

Flagship Plan

Mepolizumab Therapy (12 months)

Anti-IL-5 monthly injection for eosinophilic severe asthma.

Wait Time

5-7 days

Hospital Stay

12 monthly doses

Recovery

Outpatient

Estimated Price

Approx. $8,500/year

View Detailed Introduction — Procedure, Price Comparison & More

Price Comparison: China vs. USA

🇨🇳 China

$6,000

🇺🇸 USA

$30,000+

Save up to $24,000 per treatment

Procedure Steps

Pre-treatment: blood eosinophil count + IgE + FeNO + spirometry

Rule out other eosinophilic conditions (EGPA, parasitic)

Initial injection at infusion center: mepolizumab 100mg SC

Monthly SC injections at home after training (or clinic)

Every 3 months: asthma control assessment (ACT/ACQ)

Biomarker monitoring: eos count should decrease 80%+

Assess response at 4 months — continue if improvement

Step-down OCS and ICS doses based on control

What is Mepolizumab?

An anti-IL-5 monoclonal antibody that dramatically reduces exacerbations in severe eosinophilic asthma, COPD with eosinophilia, EGPA (Churg-Strauss), and hypereosinophilic syndrome. It targets the master regulator of eosinophil production.

Why China?

Cost (annual): $6,000-$12,000 vs. $30,000-$45,000 in the US
Biologics available: Mepolizumab, benralizumab, omalizumab all NMPA-approved
Severe asthma centers: West China, Zhongshan, PUMC — specialized units
Combination approach: Optimize inhaler technique + comorbidity management before escalating

Who is a candidate?

Severe eosinophilic asthma (≥150 eos/μL, recurrent exacerbations despite high-dose ICS/LABA)
Prednisone-dependent asthma
EGPA (Churg-Strauss)
Hypereosinophilic syndrome

Outcomes

Exacerbation reduction: 50-60%. Oral steroid reduction: 50-75%. Asthma control score improvement: clinically significant in 60-70%. Maintenance of response: durable with continued therapy.

Book Free Consultation WhatsApp

Prices are indicative ranges in USD based on partner hospital published rates. Final quote depends on your medical records and selected hospital — request a free personalized estimate.